Intravitreal ranibizumab appeared to be an effective treatment of CNV related to chronic CSC. However, residual intraretinal or subretinal fluid and increased choroidal permeability persisted. Prospective controlled studies are warranted to evaluate the long-term safety and efficacy of intravitreal ranibizumab.
No takes yet. Share an insight, caveat, or question.
Konstantinidis et al. (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: